CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses.

Th17 responses are critical to a variety of human autoimmune diseases, and therapeutic targeting with monoclonal antibodies against IL-17 and IL-23 has shown considerable promise. Here, we report data to support selective bromodomain blockade of the transcriptional coactivators CBP (CREB binding pro...

সম্পূর্ণ বিবরণ

গ্রন্থ-পঞ্জীর বিবরন
প্রধান লেখক: Hammitzsch, A, Tallant, C, Fedorov, O, O'Mahony, A, Brennan, P, Hay, D, Martinez, F, Al-Mossawi, M, de Wit, J, Vecellio, M, Wells, C, Wordsworth, B, Müller, S, Knapp, S, Bowness, P
বিন্যাস: Journal article
ভাষা:English
প্রকাশিত: National Academy of Sciences 2015

অনুরূপ উপাদানগুলি